You are here:
Rob has particular interests in:
Level 1, 242 Hopper’s Lane
(03) 9908 2999
(03) 8742 7788
He has been principal investigator on multiple research studies and numerous first-in-man cardiac technologies ranging novel coronary drug eluting and bioabsorbable stents, TAVI ( percutaneous valve implants) and pioneered renal sympathetic denervation (RDN), as Principal Investigator for the Symplicity HTN1 study, performing the first cases of RDN in the world.
He has a substantial publication track record, is an author of more than 150 papers, has given numerous invited lectures at national and international scientific meetings with substantial research funding success.
Professionally, Prof. Whitbourn is extremely active. He is on the Interventional Working group of the CSANZ, on the Executive of ANZET (Australia & New Zealand Endovascular Therapies) Group as a founding member and is Chair of the Live Case Program for the annual ANZET meeting.
Download Professor Robert Whitbourn's profile here.